HRP20201710T1 - Tolerogeno dna cjepivo - Google Patents

Tolerogeno dna cjepivo Download PDF

Info

Publication number
HRP20201710T1
HRP20201710T1 HRP20201710TT HRP20201710T HRP20201710T1 HR P20201710 T1 HRP20201710 T1 HR P20201710T1 HR P20201710T T HRP20201710T T HR P20201710TT HR P20201710 T HRP20201710 T HR P20201710T HR P20201710 T1 HRP20201710 T1 HR P20201710T1
Authority
HR
Croatia
Prior art keywords
plasmid
sequence
tgf
encodes
sequence encoding
Prior art date
Application number
HRP20201710TT
Other languages
English (en)
Inventor
Jay Chaplin
Michael Wijaranakula
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/077949 external-priority patent/WO2018083111A1/en
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of HRP20201710T1 publication Critical patent/HRP20201710T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/60—Vectors containing traps for, e.g. exons, promoters
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)

Claims (14)

1. Plazmid, naznačen time što kodira: i. inzulinski antigen; ii. TGF-β; iii. IL-10; i gdje navedeni plazmid dodatno pogoni ekspresiju interleukina-2 (IL-2).
2. Plazmid u skladu s patentnim zahtjevom 1, naznačen time što se navedeni inzulinski antigen bira iz skupine koju čine: proinzulin, preproinzulin, te njegov funkcionalni ili imunodominantni peptidni fragment.
3. Plazmid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je navedeni inzulinski antigen endosomno ciljani inzulin.
4. Plazmid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni plazmid pogoni ekspresiju inzulinskog antigena i TGF-β u količini najmanje 2 puta manjoj nego IL-10.
5. Plazmid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni plazmid sadrži: (i) FMDV 2A element koji razdvaja slijed koji kodira inzulinski antigen i slijed koji kodira TGF-β, (ii) EMCV IRES element koji razdvaja slijed koji kodira TGF-β i slijed koji kodira IL-10, te (iii) 2A element koji razdvaja slijed koji kodira IL-10 i slijed koji kodira IL-2.
6. Plazmid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što slijed koji kodira TGF-β kodira konstitutivno aktivni TGF-β.
7. Plazmid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni plazmid sadrži: (i) endosomno ciljani slijed koji kodira preproinzulin, (ii) FMDV 2A element, (iii) slijed koji kodira TGF-β, (iv) EMCV IRES element, (v) slijed koji kodira IL-10, (vi) P 2A element, (vii) slijed koji kodira IL-2, (viii) poliadenilacijski/terminacijski element, (ix) selekcijski gen, (x) početak replikacije, (xi) eukariotski promotorski element, (xii) eukariotski slijed za početak translacije, (xiii) slijed za endosomsko sortiranje sequence, te (xiv) izborno intron.
8. DNA imunoterapijsko cjepivo, naznačeno time što sadrži plazmid u skladu s bilo kojim od prethodnih patentnih zahtjeva.
9. DNA imunoterapijsko cjepivo u skladu s patentnim zahtjevom 8, ili plazmid u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačeni time što su namijenjeni upotrebi u odgađanju ili sprječavanju dijabetesa tip I.
10. DNA imunoterapijsko cjepivo u skladu s patentnim zahtjevom 8, ili plazmid u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačeni time što su namijenjeni supkutanoj primjeni.
11. DNA imunoterapijsko cjepivo u skladu s patentnim zahtjevom 8, ili plazmid u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačeni time što su namijenjeni intramuskularnoj primjeni.
12. Farmaceutski pripravak, naznačen time što sadrži DNA imunoterapijsko cjepivo u skladu s patentnim zahtjevom 8, ili plazmid u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačen time što navedeni farmaceutski pripravak sadrži fiziološku otopinu i/ili pufer i/ili kelator.
13. Farmaceutski pripravak u skladu s patentnim zahtjevom 12, naznačen time što navedeni pufer ne sadrži viruse, lipidna sredstva za supakiranje ili kondenzacijska sredstva.
14. Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 12-13, naznačen time što navedeni pripravak dodatno sadrži agonist GLP-1R.
HRP20201710TT 2016-11-01 2020-10-23 Tolerogeno dna cjepivo HRP20201710T1 (hr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662415717P 2016-11-01 2016-11-01
EP17150037 2017-01-02
EP17169019 2017-05-02
EP17177289 2017-06-22
EP17198041 2017-10-24
PCT/EP2017/077949 WO2018083111A1 (en) 2016-11-01 2017-11-01 Tolerogenic dna vaccine
EP17801363.7A EP3534936B1 (en) 2016-11-01 2017-11-01 Tolerogenic dna vaccine

Publications (1)

Publication Number Publication Date
HRP20201710T1 true HRP20201710T1 (hr) 2020-12-25

Family

ID=60190888

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201710TT HRP20201710T1 (hr) 2016-11-01 2020-10-23 Tolerogeno dna cjepivo

Country Status (24)

Country Link
US (1) US11466278B2 (hr)
EP (3) EP3534936B1 (hr)
JP (3) JP7084388B2 (hr)
KR (1) KR102476552B1 (hr)
CN (3) CN109922827B (hr)
AU (1) AU2017353323B2 (hr)
BR (1) BR112019007408A2 (hr)
CA (1) CA3042321A1 (hr)
CL (1) CL2019001181A1 (hr)
CO (1) CO2019004193A2 (hr)
DK (1) DK3534936T3 (hr)
ES (2) ES2829574T3 (hr)
HR (1) HRP20201710T1 (hr)
HU (1) HUE051766T2 (hr)
IL (1) IL266237B (hr)
MX (1) MX2019004774A (hr)
MY (1) MY190102A (hr)
PE (1) PE20190841A1 (hr)
PH (1) PH12019500851A1 (hr)
PL (1) PL3534936T3 (hr)
RS (1) RS61138B1 (hr)
RU (1) RU2752608C2 (hr)
SA (1) SA519401615B1 (hr)
SI (1) SI3534936T1 (hr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
IL266237B (en) * 2016-11-01 2022-08-01 Novo Nordisk As Tolerogenic DNA composition
US11279745B2 (en) 2019-04-26 2022-03-22 Novo Nordisk A/S Tolerogenic DNA vaccine
CN113461796A (zh) * 2021-08-04 2021-10-01 深圳晶蛋生物医药科技有限公司 一种重组sglt2蛋白及其应用
CN118139655A (zh) * 2021-08-13 2024-06-04 特里奥万斯控股公司 皮肤替代组合物及其产生和使用方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518395D0 (en) * 1995-09-08 1995-11-08 Therexsys Ltd Plasmid stabilization
US6083919A (en) 1996-12-05 2000-07-04 University Of Florida Materials and methods for treating autoimmune disease
US7030098B2 (en) 1999-03-12 2006-04-18 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for treatment of autoimmune disease
US6884785B2 (en) 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes
AU2001253746A1 (en) 2000-04-20 2001-11-07 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Inducible plasmid vector encoding tgf-beta and uses thereof
EP2329846B1 (en) * 2000-09-08 2014-11-12 University Of Maryland, Baltimore Genetically engineered co-expression DNA vaccines, construction methods and uses thereof
USD459798S1 (en) 2001-03-26 2002-07-02 Aventis Pharma S.A. Pill tablet
SE0102204D0 (sv) 2001-06-21 2001-06-21 Leif Isaksson New method
US7544669B2 (en) 2001-11-21 2009-06-09 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
AU2003278695A1 (en) 2002-05-28 2004-02-02 Maxygen, Inc. Nucleic acid vectors
RU2228198C1 (ru) * 2002-08-21 2004-05-10 Полетаев Александр Борисович Способ коррекции патологического аутоиммунного процесса при сахарном диабете
EP2322186A3 (en) 2002-11-21 2011-07-13 Bayhill Therapeutics, Inc. Methods and immune modulatory nucleic acid compositions for preventing and treating disease
US20050026189A1 (en) 2003-05-29 2005-02-03 Liangsu Wang Microbial operons
US20050147621A1 (en) 2003-10-10 2005-07-07 Higgins Darren E. Use of bacterial 5' untranslated regions for nucleic acid expression
WO2005089101A2 (en) 2004-02-03 2005-09-29 Dana-Farber Cancer Institute, Inc. Non-pathogenic listeria vaccine vectors and methods of treatment therewith
CN101277722A (zh) * 2005-08-06 2008-10-01 王庆华 用于预防和治疗ⅰ型糖尿病的组合物及方法
CN101365494A (zh) 2005-10-05 2009-02-11 贝希尔治疗学股份有限公司 治疗自身免疫性疾病的组合物和方法
CA2550133A1 (en) 2006-02-16 2007-08-16 The Governors Of The University Of Alberta Temperature regulated gene expression
US20100048679A1 (en) 2006-06-13 2010-02-25 Bayhill Therapeutics, Inc. Polynucleotide therapy
US9339500B2 (en) 2008-03-04 2016-05-17 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
US9217153B2 (en) 2009-05-22 2015-12-22 Merial, Inc. Antibiotic-free plasmids
AU2010278702C1 (en) 2009-07-31 2016-07-14 Forsyth Dental Infirmary For Children Programming of cells for tolerogenic therapies
JP2013517329A (ja) 2010-01-20 2013-05-16 ベイヒル セラピューティクス インコーポレーティッド 自己免疫疾患を処置するための併用治療
CN103200959A (zh) 2010-09-27 2013-07-10 中国农业大学 预防和治疗自身免疫性疾病的联合抗原和dna疫苗
WO2012062697A1 (en) * 2010-11-08 2012-05-18 Novartis Ag Combination therapy for type 1 diabetes
EP2753362A4 (en) 2011-09-08 2015-04-15 Univ Florida MATERIALS AND METHODS FOR MODULATING THE IMMUNE RESPONSE
WO2014035457A1 (en) 2012-08-29 2014-03-06 Nature Technology Corporation Dna plasmids with improved expression
US9636386B2 (en) 2013-03-15 2017-05-02 City Of Hope Attenuated Salmonella bacteria and methods of using
WO2016057986A1 (en) * 2014-10-10 2016-04-14 The Trustees Of Columbia University In The City Of New York Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof
WO2016162385A1 (en) 2015-04-07 2016-10-13 Consejo Superior De Investigaciones Científicas (Csic) Bacterial system for the identification of amyloidogenic peptides and the screening of inhibitors of amyloidosis
EP3556847B1 (de) 2015-12-11 2021-03-03 Wacker Chemie AG Mikroorganismenstamm und verfahren zur antibiotikafreien, fermentativen herstellung von niedermolekularen substanzen und proteinen
IL266237B (en) * 2016-11-01 2022-08-01 Novo Nordisk As Tolerogenic DNA composition
TWI728201B (zh) 2016-11-01 2021-05-21 丹麥商諾佛 儂迪克股份有限公司 耐受性ｄｎａ疫苗
USD813372S1 (en) 2017-02-22 2018-03-20 Celgene Corporation Pharmaceutical tablet
US11279745B2 (en) 2019-04-26 2022-03-22 Novo Nordisk A/S Tolerogenic DNA vaccine

Also Published As

Publication number Publication date
RU2752608C2 (ru) 2021-07-29
US11466278B2 (en) 2022-10-11
AU2017353323B2 (en) 2024-02-29
EP3799882A1 (en) 2021-04-07
US20190241898A1 (en) 2019-08-08
CN109922827B (zh) 2024-03-01
CO2019004193A2 (es) 2019-07-31
HUE051766T2 (hu) 2021-03-29
SA519401615B1 (ar) 2023-01-31
MY190102A (en) 2022-03-28
JP6721790B2 (ja) 2020-07-15
EP3535399A1 (en) 2019-09-11
JP7084388B2 (ja) 2022-06-14
PL3534936T3 (pl) 2021-01-25
IL266237A (en) 2019-06-30
PH12019500851A1 (en) 2019-12-02
MX2019004774A (es) 2019-08-05
CN109890967A (zh) 2019-06-14
CN109890967B (zh) 2024-03-19
EP3535399B1 (en) 2020-10-07
KR102476552B1 (ko) 2022-12-13
ES2829574T3 (es) 2021-06-01
ES2834329T3 (es) 2021-06-17
SI3534936T1 (sl) 2020-12-31
KR20190076020A (ko) 2019-07-01
RU2019115540A3 (hr) 2021-01-28
IL266237B (en) 2022-08-01
JP2020062057A (ja) 2020-04-23
CA3042321A1 (en) 2018-05-11
CN109922827A (zh) 2019-06-21
RU2019115540A (ru) 2020-12-03
EP3534936B1 (en) 2020-10-21
CL2019001181A1 (es) 2019-07-05
EP3534936A1 (en) 2019-09-11
JP2019532659A (ja) 2019-11-14
RS61138B1 (sr) 2020-12-31
PE20190841A1 (es) 2019-06-17
AU2017353323A1 (en) 2019-05-02
BR112019007408A2 (pt) 2019-07-02
JP2019532660A (ja) 2019-11-14
DK3534936T3 (da) 2020-11-02
CN118086388A (zh) 2024-05-28

Similar Documents

Publication Publication Date Title
HRP20201710T1 (hr) Tolerogeno dna cjepivo
RU2016146801A (ru) Вакцинная композиция против инфекции, вызванной streptococcus suis
Zhou et al. Intrinsic 4-1BB signals are indispensable for the establishment of an influenza-specific tissue-resident memory CD8 T-cell population in the lung
EP2215269B1 (en) Construct system and uses therefor
JP2019532659A5 (hr)
JP2015166353A5 (hr)
AU2019250180A1 (en) CMV glycoproteins and recombinant vectors
HRP20211566T1 (hr) Antigeni, vektori, pripravci virusa humane imunodeficijencije i postupci njihove uporabe
JP2018524393A5 (hr)
JP2020528911A5 (hr)
JP2006512097A5 (hr)
JP2017530124A5 (hr)
CA3087442A1 (en) Formulation for administration of rna
JP2021509107A (ja) Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよびその使用
AU2017297822A1 (en) Formulation for administration of RNA
EA201591213A1 (ru) Вакцины против вируса гепатита b
Robertsen et al. IFN-adjuvanted DNA vaccine against infectious salmon anemia virus: Antibody kinetics and longevity of IFN expression
WO2013067652A1 (en) Facilitator-dna combination vaccine
RU2021109510A (ru) Вакцинация с использованием альфа 3 домена mica/b для лечения рака
WO2005046621A3 (en) Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
Pedersen et al. Stimulation of type I IFN activity in Atlantic salmon (Salmo salar L.) leukocytes: synergistic effects of cationic proteins and CpG ODN
KR20240023600A (ko) 바이러스 질환을 위한 온도-제어가능한, 자기-복제 rna 백신
JP2017516462A5 (hr)
JP2013512256A5 (hr)
JP2010510218A5 (hr)